Hansoh Pharmaceutical's (HKG:3692) risvutatug rezetecan for injection was included in the priority review and approval procedure of China's National Medical Products Administration.
The move followed positive results from a phase 3 trial of the drug for small cell lung cancer, according to a Friday bourse disclosure.